Investigated for use/treatment in cervical dysplasia/cancer, viral infection, and vulvar dysplasia and carcinoma.
How Tipapkinogene Sovacivec works
TG 4001 is based on the modified vaccinia virus Ankara (MVA virus) carrying and expressing HPV16 E6 and E7 genes. The MVA vector is a highly attenuated strain of vaccinia virus that combines an extensive history of safety with the ability to stimulate a strong immune response to antigens. The TG 4001 therapeutic vaccine induces specific immunity by presentation of E6 and E7 antigens to T cells via major histocompatibility complex (MHC) class I and II inducing specific cellular and humoral responses. A second mechanism may be a non-specific activation of the immune system via the vaccinia virus and the interleukin 2 (IL2) adjuvant of the immune response. TG 4001 could have further applications beyond Cervical Intraepithelial Neoplasia (CIN) 2/3 as a single agent in low grade CIN (CIN1) or cervical cancers in combination with existing treatments. [Transgene press release]
|Trade Name||Tipapkinogene Sovacivec|
|Tipapkinogene sovacivec Other Names||MVA-HPV-IL2 vaccine, Tipapkinogene sovacivec|
|Last Updated:||August 5, 2021 at 12:40 pm|